nach oben

Erschienen in:

Open Access 01.12.2023 | Research article

Triangulating evidence from observational and Mendelian randomization studies of ketone bodies for cognitive performance

verfasst von: Wichanon Sae-jie, Suangsuda Supasai, Mika Kivimaki, Jackie F. Price, Andrew Wong, Meena Kumari, Jorgen Engmann, Tina Shah, Amand F. Schmidt, Tom R. Gaunt, Aroon Hingorani, Pimphen Charoen, on behalf of the UCLEB Consortium

Erschienen in: BMC Medicine | Ausgabe 1/2023

Abstract

Background

Ketone bodies (KBs) are an alternative energy supply for brain functions when glucose is limited. The most abundant ketone metabolite, 3-β-hydroxybutyrate (BOHBUT), has been suggested to prevent or delay cognitive impairment, but the evidence remains unclear. We triangulated observational and Mendelian randomization (MR) studies to investigate the association and causation between KBs and cognitive function.

Methods

In observational analyses of 5506 participants aged ≥ 45 years from the Whitehall II study, we used multiple linear regression to investigate the associations between categorized KBs and cognitive function scores. Two-sample MR was carried out using summary statistics from an in-house KBs meta-analysis between the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium and Kettunen et al. (N = 45,031), and publicly available summary statistics of cognitive performance and Alzheimer’s disease (AD) from the Social Science Genetic Association Consortium (N = 257,841), and the International Genomics of Alzheimer’s Project (N = 54,162), respectively. Both strong (P < 5 × 10⁻⁸) and suggestive (P < 1 × 10⁻⁵) sets of instrumental variables for BOHBUT were applied. Finally, we performed cis-MR on OXCT1, a well-known gene for KB catabolism.

Results

BOHBUT was positively associated with general cognitive function (β = 0.26, P = 9.74 × 10⁻³). In MR analyses, we observed a protective effect of BOHBUT on cognitive performance (inverse variance weighted: β_IVW = 7.89 × 10⁻², P_IVW = 1.03 × 10⁻²; weighted median: β_W-Median = 8.65 × 10⁻², P_W-Median = 9.60 × 10⁻³) and a protective effect on AD (β_IVW = − 0.31, odds ratio: OR = 0.74, P_IVW = 3.06 × 10⁻²). Cis-MR showed little evidence of therapeutic modulation of OXCT1 on cognitive impairment.

Conclusions

Triangulation of evidence suggests that BOHBUT has a beneficial effect on cognitive performance. Our findings raise the hypothesis that increased BOHBUT may improve general cognitive functions, delaying cognitive impairment and reducing the risk of AD.

Additional file 1: Appendix S1. List of additional UCLEB members. Supplementary Methods. Fig. S1. Hypothesized biological pathway linking ketone body metabolism and cognitive functions. During fasting, fatty acids are converted into acetoacetate (ACACE) and 3-β-hydroxybutyrate (BOHBUT) through Acetyl CoA. BOHBUT and ACACE cross the blood-brain barrier (BBB) and enter neurons through a monocarboxylate transporter (MCT) channel. Once BOHBUT and ACACE enter the brain, a series of reactions occur to form Acetyl CoA. These reactions involve the 3-oxoacid CoA-transferase 1 (OXCT1) enzyme which is encoded by the OXCT1 gene. The product of OXCT1 is then converted to acetyl-CoA and subsequently enters the tricarboxylic acid (TCA) cycle for oxidation and ATP production [5]. BOHBUT and ACACE have been suggested to contribute to the secretion of Brain-derived neurotrophic factor (BDNF). This protein molecule is involved in the enhancement of mitochondrial biogenesis and synaptic plasticity, a key to learning ability and memory [6,7]. Table S1. Details of studies and datasets included in analyses. Table S2.Baseline characteristics of participants in the WHII study. Table S3. Multiple linear regression examining the association between BOHBUT and ACACE as a continuous variable and cognitive function scores. The models were adjusted by age, sex, diabetes (yes/no), smoking (ever/never), alcohol consumption (heavy/other), waist-to-hip ratio, and socioeconomic status (low/intermediate/high). Table S4. SNPs associated with ACACE using clumping windows -/+ 10 000 kb and r² < 0.001. Table S5. SNPs associated with BOHBUT using clumping window -/+ 10 000 kb and r²< 0.001. Table S6. SNPs associated with ACACE using clumping window -/+ 10 000 kb and r²< 0.001. Table S7. Association analyses between 3-β-hydroxybutyrate instrumental SNPs and potential confounders, including alcohol (ever/never), diabetes (yes/no), adiposity, i.e., waist-to-hip ratio, and occupational position (low/intermediate/high). Table S8. Association analyses between acetoacetate instrumental SNPs and potential confounders, including alcohol (ever/never), diabetes (yes/no), adiposity, i.e., waist-to-hip ratio, and occupational position (low/intermediate/high). Table S9. MR of BOHBUT on cognitive performance and Alzheimer’s disease using 5 instrumental SNPs associated with BOHBUT (GWAS threshold: P< 5 × 10^-8). Table S10. MR of BOHBUT on cognitive performance and Alzheimer’s disease using 19 instrumental SNPs associated with BOHBUT (GWAS threshold: P < 1 × 10^-5).Table S11. Heterogeneity and pleiotropy tests in MR of BOHBUT on cognitive performance and Alzheimer’s disease. Table S12. MR of ACACE on cognitive performance and Alzheimer’s disease using 3 instrumental SNPs associated with ACACE (GWAS threshold: P < 5 × 10^-8). Table S13. MR of ACACE on cognitive performance and Alzheimer’s disease using 14 instrumental SNPs associated with ACACE (GWAS threshold: P < 1 × 10^-5). Table S14. Heterogeneity and pleiotropy tests in MR of ACACE on cognitive performance and Alzheimer’s disease. Table S15. MR of BOHBUT on cognitive performance and Alzheimer’s disease using 4 instrumental SNPs (rs6982503 was removed) associated with BOHBUT (GWAS threshold: P < 5 × 10^-8). Table S16. cis-SNPs in OXCT1 (GWAS threshold: P < 1 × 10^-5) using clumping window -/+ 10 000 kb and LD-r² < 0.4. Table S17. cis-MR for a causal estimate of OXCT1 locus on cognitive performance and Alzheimer’s disease.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-023-03047-7.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ACACE

Acetoacetate

Alzheimer’s disease

Aβ

β-Amyloid

BDNF

Brain-derived neurotrophic factor

BOHBUT

3-β-Hydroxybutyrate

GWAS

Genome-wide association studies

IGAP

International Genomics of Alzheimer’s Project

IQR

Interquartile range

IVW

Inverse variance weighted

KBs

Ketone bodies

Mendelian randomization

MR-PRESSO

Mendelian Randomization Pleiotropy RESidual Sum and Outlier

NMR

Nuclear magnetic resonance

Odds ratio

OXCT1

3-Oxoacid CoA transferase 1

RCTs

Randomized controlled trials

SCOT

Succinyl-CoA:3-ketoacid CoA transferase

SNPs

Single nucleotide polymorphisms

SSGAC

Social Science Genetic Association Consortium

UCLEB

University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol

WHII

Whitehall II study

W-Median

Weighted median method

W-Mode

Weighted mode-based estimation method

Background

Apart from glucose, ketone bodies (KBs) can cross the blood–brain barrier and are considered to be alternative energy in maintaining brain functions [1]. 3-β-Hydroxybutyrate (BOHBUT), one of the most abundant KBs, has been reported to enhance cognitive abilities [2]. BOHBUT plays crucial roles in brain energy supply at the low glucose [3], neurotransmitter regulation [4, 5], reduction of oxidative stress [6], and preventing neuronal cells from pathogenic cellular proteins, including β-amyloid (Aβ) and phosphorylated tau [7, 8] that can contribute to neurodegenerative diseases.

Many studies have suggested that dietary BOHBUT supplementation may have a positive effect on cognitive function. In small experimental studies, BOHBUT enhanced cognitive memory in patients with type 2 diabetes [9]. In addition, BOHBUT showed positive outcomes on memory functions in older adults free of dementia [10], patients with mild cognitive impairment [11], and those with mild-to-moderate Alzheimer’s disease (AD) [8, 12]. Small randomized controlled trials (RCTs) also suggested KB treatment in both AD and diabetes patients may provide neuroprotection [9, 11, 12]. In studies on mice, it was shown that BOHBUT promoted hippocampal brain-derived neurotrophic factor (BDNF) expression (4, 5), a protein which is positively associated with neuronal survival, neurotransmitter regulation, synaptic plasticity, and memory formation whereas a decrease in BDNF is linked to increased risk of neurodegenerative diseases [13, 14]. The hypothesized biological pathway connecting KB metabolism and cognitive functions is shown in Additional file 1: Fig. S1. In addition, BOHBUT has been reported to enhance learning and memory in AD transgenic mice via improvement in neuronal mitochondrial energy [15]. It is unclear whether KBs improve cognitive performance or prevent or delay cognitive impairment in humans as studies verifying the results across disparate lines of evidence are missing, a technique known as triangulation.

In this study, we present a triangulation of evidence using observational studies and Mendelian randomization (MR) studies to assess evidence of the causality of BOHBUT on cognitive performance. First, we used an observational study to investigate the associations between BOHBUT and cognitive functions. Second, we performed MR analyses (a method of using measured variation in associated genes to examine the causal effect of a modifiable exposure on disease in observational studies) to assess the causal relationships of BOHBUT with cognitive performance and AD, a disorder characterized by cognitive impairment. In addition to BOHBUT, we also performed parallel analyses on acetoacetate (ACACE), a precursor to BOHBUT. After fatty acids are broken down in the liver, ACACE is produced before converting to BOHBUT [16, 17]. ACACE is known as an unstable compound that becomes rapidly decarboxylated and is produced in a small amount; thus, it is a less reliable measurement for KBs compared to BOHBUT [18].

Methods

Observational study

Datasets for observational study

To assess the association between KBs and cognitive functions, we used the Whitehall II study (WHII) including 5506 participants from the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium [19] (Fig. 1, Additional file 1: Table S1). Out of the initial 5506 samples, there were 4621 samples with BOHBUT and 4637 sample with ACACE. We exclusively used complete cases in the observational analysis, i.e. individuals with missing covariate data were excluded. Therefore, there were 2214 samples in the BOHBUT observational analysis and 2224 samples in the ACACE observational analysis. Both KB and cognitive functions were measured at baseline (details in Additional file 1: Supplementary Method).

Nuclear magnetic resonance (NMR) spectroscopy was used to measure circulating BOHBUT and ACACE from serum collected after fasting for at least 8 h. Samples that did not meet the quality control criteria during the automated data processing on the NMR platform were excluded. For instance, this applied to those exhibiting degradation and contamination issues. We did not observe any 0 mmol/L of KB values in WHII which could be obtained from the standard procedure in the platform to set metabolite value to zero when its concentration was above the limit of detection but below the limit of quantification due to biological reasons or external compounds interfering with the quantification.

Three types of cognitive function scores were measured using the following psychometric assessments. Word memory was assessed by recalling a list of 20 words that participants heard in 2 min (N = 3115). Verbal fluency was assessed by naming as many animals as possible within 1 min (N = 3122). Verbal meaning was assessed by answering multiple choice questions for 33 stimulus words ordered by increasing difficulty (N = 3142). The details of the protocol are reported in Elovainio et al. [20].

Observational analyses

For an outcome, we calculated the “general” cognitive performance score to obtain comparable results to our MR analyses for which we obtained publicly available summary statistics from cognitive performance meta-analysis in the Social Science Genetic Association Consortium (SSGAC) [21]. By avoiding taking more than one cognitive test score from any individual cognitive test, the principal component analysis was applied to cognitive test scores to derive a measure of “general” cognitive performance. The scores on the first unrotated component were used as the general cognitive function [22, 23]. Therefore, using a similar approach, we calculated the scores on the first unrotated component based on verbal meaning, verbal fluency, and word memory in WHII. In addition, the scores from each cognitive test, including verbal meaning, verbal fluency, and word memory, were also used as outcomes in observational analyses.

For exposure, we categorized KBs into two groups, e.g., high vs normal levels, based on the assumption that KBs could have a therapeutic benefit when the concentrations reach a certain level [24]. Due to the unknown cutoff, we varied the thresholds across the KB range. Association analysis between categorized KBs and cognitive function scores was performed using multiple linear regression. Age; sex; diabetes (yes/no); smoking (ever/never); alcohol consumption (heavy/other); adiposity, i.e., waist-to-hip ratio; and occupational position (low/intermediate/high) were used as covariates. KB cutoff was varied under the range that allows the minimum 90% statistical power under the two-sample t-test. The unit for the regression coefficient of KB was reported as the standard deviation of cognitive scores per KB group exceeding the cutoff.

Association analyses between continuous KBs and cognitive function scores were also reported. The same set of covariates was applied, and the unit for the regression coefficient of KB was reported as the standard deviation of cognitive scores per 1 mmol/L of KB. As we performed association analyses across 3 different cognitive performances which are not highly correlated (cor_{Fluency-Memory} = 0.32, cor_{Fluency-Meaning} = 0.46, and cor_{Memory-Meaning} = 0.22), a Bonferroni-corrected significance threshold of 0.05/3 = 0.0167 was applied to adjust for multiple testing. A P-value < 0.05 was considered a suggestive association, requiring confirmation.

Mendelian randomization study

Datasets for Mendelian randomization

A two-sample MR analysis was applied to incorporate available summary statistics from two genome-wide association studies (GWAS) with non-overlapping samples for exposure and outcome.

Exposure data: ketone bodies

We obtained genetic instruments and their summary statistics from our in-house KB meta-analysis between the UCLEB Consortium [19] and Kettunen et al. [25] involving 45,031 participants (Fig. 1, Additional file 1: Supplementary Method). Two sets of single nucleotide polymorphisms (SNPs) as instrumental variables were used: (1) a strong set of instrumental SNPs (P < 5 × 10⁻⁸) and (2) a suggestive set of instrumental SNPs (P < 1 × 10⁻⁵). All instrumental SNPs were ensured independence using r² < 0.001 with a clumping window of 10,000 kb. European samples in the 1000 Genomes Project were used as a reference panel for calculating linkage disequilibrium [26].

Outcome data: cognitive performance

Summary statistics for SNPs associated with cognitive performance and AD were retrieved from the publicly available data. Cognitive performance involving 257,841 participants was extracted from the SSGAC Consortium [21], and AD involving 54,162 participants was from the International Genomics of Alzheimer’s Project (IGAP) [27]. The details of demographics and GWAS analyses for cognitive performance and AD were provided in Additional file 1: Table S1.

Two-sample Mendelian randomization analyses

Firstly, we applied the conventional inverse variance weighted (IVW) method. A random-effect IVW was applied when there was evidence of heterogeneity using Cochran’s Q test (P < 0.1); otherwise, a fixed-effect IVW was applied [28]. For sensitivity analyses, we applied various methods to assess the robustness of results when MR assumptions are deviated: weighted median method (W-Median), weighted mode-based estimation method (W-Mode), MR-Egger regression, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO). The W-Median method provides valid causal estimates under the assumption that at least half of the contributing information comes from genetic variants that are valid instruments [29]; the W-Mode method allows an unbiased effect estimate when the most common causal effect estimate is consistent with the true causal effect, even if the majority of instruments are invalid [30]; MR-Egger can identify and control for bias due to directional pleiotropy [31]; and MR-PRESSO can detect and correct the effects of outliers that could bias the results [32]. In these analyses, R² represents the proportion of variance in liability to KBs explained by SNPs. We reported F-statistics to evaluate the strength of instrumental SNPs. The strong set of instruments (F-statistic > 10) is desirable; nevertheless, the exclusion of weak instruments may introduce more bias than prevents [33]. Lastly, we conducted cis-MR using SNPs with P < 1 × 10⁻⁵ (r² < 0.4) and located within 100 kb around the encoding genes and applied IVW and MR-Egger methods accounting for residual correlation [34]. The analyses were performed using the “TwoSampleMR” [26] and the “MendelianRandomization” [35] packages in R.

Results

Participant characteristics

Descriptive statistics on the characteristics of the WHII are shown in Additional file 1: Table S2. Participants were European, aged 44 to 70 years, and 72% of them were men. The median of BOHBUT was 0.116 mmol/L (interquartile range: IQR 0.092), and ACACE was 0.044 mmol/L (IQR 0.043). The cognitive function scores were standardized (mean = 0, SD = 1) to allow comparison between tests.

Observational study

Using regression analysis adjusted for age, sex, diabetes, smoking, alcohol consumption, waist-to-hip ratio, and occupational position with varying KB cutoffs, when BOHBUT reached 0.32 mmol/L, we observed strong evidence of association (P < 0.0167) between BOHBUT and general cognitive function (β_max = 0.257, P = 9.74 × 10⁻³ at the cutoff 0.35 mmol/L). For each cognitive function, we observed evidence of the suggestive association between BOHBUT and verbal meaning when BOHBUT reached 0.32 mmol/L (β_max = 0.136, P = 3.27 × 10⁻² at the cutoff 0.32 mmol/L), while no evidence can be found in verbal fluency and word memory directly (Fig. 2).

For ACACE, a strong association between ACACE and general cognitive function was observed when ACACE reached 0.15 mmol/L (β_max = 3.40, P = 6.69 × 10⁻³ at the cutoff 0.165 mmol/L). For each cognitive function, we also found a suggestive association between ACACE and verbal meaning (β_max = 0.119, P = 1.77 × 10⁻² at the cutoff 0.1 mmol/L). No clear evidence of association was observed in relation to verbal fluency and word memory (Fig. 2).

In addition, we performed association analyses between BOHBUT as a continuous variable and cognitive function scores with the same covariant adjustment. Little evidence of association was shown in general cognitive function (β = 0.318, P = 0.15), verbal meaning (β = 0.292, P = 7.28 × 10⁻²), verbal fluency (β = 0.097, P = 0.591), and word memory (β = 0.156, P = 0.412) (Additional file 1: Table S3).

Using ACACE as a continuous variable, positive effects were found in association analyses between ACACE and verbal meaning (β = 1.152, P = 4.59 × 10⁻³) and suggestive evidence between ACACE and general cognitive function (β = 1.285, P = 1.97 × 10⁻²). Little evidence can be observed in verbal fluency (β = 0.716, P = 0.113) and word memory (β = 0.253, P = 0.596) (Additional file 1: Table S3).

Mendelian randomization study

Selection of instrumental variants

Table 1 presents the five independent selected SNPs associated with BOHBUT at a genome-wide significance level (P < 5 × 10⁻⁸). Using five instrumental SNPs for BOHBUT, the variance explained by genetics was 0.6%, and the F-statistic was 54.59. One of these SNPs is rs1508816, close to the well-known 3-oxoacid CoA transferase 1 (OXCT1) gene producing the key enzyme for ketone body catabolism. For ACACE, three independent SNPs were shown at a genome-wide significance level (Additional file 1: Table S4) with the variance explained by the genetics of 0.5% and the F-statistic of 72.24. For the suggestive set of instrumental variables (P < 1 × 10⁻⁵), 19 and 14 independent SNPs were identified for BOHBUT and ACACE, respectively (Additional file 1: Table S5 and S6).

Table 1

SNPs associated with 3-β-hydroxybutyrate under GWAS significance thresholds at P < 5 × 10⁻⁸

SNPs	Chr	Closest reference gene^a	Beta coefficient	SE	P-value (discovery stage)	Effect allele	Effect allele frequency
Association with P < 5 × 10⁻⁸
rs9302635	16	DHX38	− 0.083	0.009	6.59 × 10⁻²¹	T	0.820
rs9987289	8	PPP1R3B	− 0.084	0.011	3.42 × 10⁻¹⁴	A	0.105
rs1508816	5	(OXCT1)	0.052	0.008	5.04 × 10⁻¹¹	T	0.745
rs2419604	10	GPAM	− 0.050	0.008	4.27 × 10⁻¹⁰	A	0.287
rs6982502	8	(TRIB1)	0.041	0.007	2.25 × 10⁻⁸	T	0.540

Sample size = 45,031

Chr Chromosome, SE Standard error

^aGenes for SNPs that are outside the transcript boundary of the protein-coding gene are shown in parentheses [e.g., (OXCT1)]

To assess instrument validity, we also performed association analyses between KB instrumental SNPs and potential confounders, including alcohol (heavy/other), diabetes (yes/no), waist-to-hip ratio, and occupational position (low/intermediate/high). After adjusting for Bonferroni correction (8 independent SNPs and 5 potential confounding factors), a significance threshold of 0.05/13 = 3.8 × 10⁻³ was applied. All instrumental SNPs were not associated with potential confounders, except for rs6982502, which was shown to be associated with smoking (ever/never) (P-value = 8.95 × 10⁻⁵) (Additional file 1: Table S7 and S8). For the robustness of results when MR assumptions are deviated, sensitivity analyses including weighted median and weighted mode methods were applied to ensure the reliability of our findings.

Causal effects of KBs on cognitive performance

Using the strong set of instrumental variables, we observed a positive association of genetically predicted BOHBUT with cognitive performance using the IVW and W-median methods (IVW: β_IVW = 7.89 × 10⁻², P_IVW = 1.03 × 10⁻², W-median: β_W-Median = 8.65 × 10⁻², P_W-Median = 9.60 × 10⁻³, W-mode: β_W-Mode = 0.126, P_W-Mode = 8.56 × 10⁻²) (Fig. 3, Additional file 1: Table S9). Evidence of causality between BOHBUT and cognitive performance was consistent by using a suggestive set of instrumental SNPs (β_IVW = 6.11 × 10⁻², P_IVW = 2.03 × 10⁻³; β_W-Median = 5.68 × 10⁻², P_W-Median = 2.30 × 10⁻²; β_W-Mode = 4.35 × 10⁻², P_W-Mode = 0.367) (Additional file 1: Table S10). The Cochran’s Q test showed no evidence of heterogeneity (P > 0.1). In addition, no evidence of directional pleiotropy or outliers was observed using MR-Egger intercept (P > 0.05) and MR-PRESSO (P > 1 × 10⁻⁶) (Additional file 1: Table S11).

We did not find evidence of causality between ACACE and cognitive performance (Additional file 1: Table S12 and S13). Directional pleiotropic effects were not observed in the MR-Egger regression, and no outlier SNP was detected in the MR-PRESSO test (Additional file 1: Table S14).

Causal effects of KBs on Alzheimer’s disease

Using a strong set of instrumental variables, we observed some evidence for a protective effect of BOHBUT on AD using IVW (β_IVW = − 0.308, odds ratio: OR = 0.735, P_IVW = 3.06 × 10⁻²). Similar causal estimates with less precision were shown using W-median (β_W-Median = − 0.319, OR = 0.727, P_W-Median = 5.43 × 10⁻²) and W-mode (β_W-Mode = − 0.327, OR = 0.721, P_W-Mode = 0.212) (Fig. 3). However, we did not observe evidence of causality under a suggestive set of instrumental SNPs (Additional file 1: Table S10). No significant causal association was observed between ACACE and AD (Additional file 1: Table S12 and S13), and evidence of directional pleiotropy and outliers was not observed (Additional file 1: Table S14).

After excluding rs6982503 previously shown an association with smoking, a potential confounding factor, the variance explained by genetics for BOHBUT was slightly reduced from 0.6 to 0.5%. The protective effect of BOHBUT on cognitive performance also remained (β_IVW = 9.26 × 10⁻², P_IVW = 3.43 × 10⁻³; β_W-Median = 0.115, P_W-Median = 9.99 × 10⁻⁴), and a similar causal estimate of BOHBUT on AD was also observed, although with less precision (β_IVW = − 0.274, OR = 0.76, P_IVW = 7.22 × 10⁻²). Evidence of neither directional pleiotropy nor outliers was observed using MR-Egger intercept and MR-PRESSO (Additional file 1: Table S15).

Causal effect estimation with cis-MR

The OXCT1 gene encodes the enzyme Succinyl-CoA:3-ketoacid CoA transferase (SCOT), which is the key reaction that enables ketone body utilization for energy production [36]. We further performed cis-MR to investigate the therapeutic modulation of OXCT1 as a partial predictor of KB. Three cis-acting SNPs (P < 1 × 10⁻⁵ and r² < 0.4) were identified close to the OXCT1 region with the variance explained of 0.19% and F-statistic of 28.40 (Additional file 1: Table S16). Accounting for the remaining residual correlation, cis-MR suggested little evidence of therapeutic modulation of OXCT1 on either cognitive performance (β_IVW = 0.038, P_IVW = 0.312) or AD (β_IVW = − 0.331, P_IVW = 0.290) while the direction of effect estimates was consistent with those previously shown (Additional file 1: Table S17). No evidence of pleiotropy was observed (P = 0.869).

Discussion

Triangulating evidence from observational and MR studies supports a beneficial causal effect of BOHBUT on cognitive performance. First, an observational study showed that a range of increased levels of BOHBUT was associated with higher general cognitive function scores. Second, using a two-sample MR, BOHBUT showed evidence for causality on cognitive performance with a positive causal effect which was in concordance with the observational study previously observed. Using the MR study, we also observed the nominal protective effect of BOHBUT against AD, which supports the protective role of BOHBUT on cognitive function.

In clinical trials, either ketogenic diet or various types of KB supplement intakes were used to investigate the therapeutic effect on neurodegenerative diseases [24, 37]. The suggested therapeutic levels of KB for Alzheimer’s and epilepsy were 0.5 mmol/L and 2 mmol/L, respectively [24]; however, no investigation was shown for an early stage of cognitive decline. In our study, by varying KB cutoffs, we observed that BOHBUT was associated with the general cognitive performance score, when its concentration reached 0.32 mmol/L. Therefore, the lower concentration of KB could give a beneficial effect at an early stage.

In our observational analysis in which KB was categorized into two groups using exploratory therapeutic thresholds, we observed an attenuated estimate when the cutoff was increased. It was previously shown that a very high concentration of KBs (> 3 mmol/L) known as ketoacidosis [24] leads to delayed brain development [38] and increased risk of dementia in type 2 diabetes patients [39]. This may imply a non-linear relationship between KB and cognitive abilities. If this is the case, other possible assumptions on a therapeutic range of KB should be further explored. In our study, the KB range measured in WHII is limited to 0–1.5 mmol/L, with 98% of samples falling within a normal BOHBUT range below 0.5 mmol/L. Consequently, this limitation constrained our exploratory analysis within the framework of an observational study. Further investigation on a non-linear MR should be explored when individual patient data is available.

Clinical examinations using mental status tests, including word memory, verbal fluency, and verbal meaning, are recommended by current diagnostic guidelines to evaluate cognitive impairment. In this present study, we investigated the association of serum BOHBUT with the general cognitive function scores obtained from these mental status tests. These mental performances involve cognitive functions mainly in the prefrontal and left frontal cortices and hippocampus [40‐42]. Perhaps further investigations are required to assess the causal role of KB on other parts of the brain, e.g., the occipital and parietal white matter that is myelinated region mediating network messaging and the processing speed [43, 44]. In addition, although we were less focused on ACACE due to its being an unstable compound [16], we still observed evidence of the association between increased ACACE and an improvement in general cognitive performance. This provided supportive evidence of what we previously observed in BOHBUT.

We further looked into downstream diseases from the progression of cognitive function decline. Unfortunately, a large GWAS for dementia was not publicly available; therefore, only AD was investigated. The protective causal effect of BOHBUT against AD was observed using IVW, and similar causal effects with less precision were shown using W-median and W-mode. This nominal protective effect gives some supportive evidence for a beneficial effect of BOHBUT on cognitive performance previously found. MR uses genetic variants as a natural experiment which is less prone to bias from confounding factors and reverse causation compared to an observational analysis, and thus, MR infers stronger evidence for causality.

Using genetic variants as an instrument, our work suggests that lifelong naturally elevated KBs have a beneficial effect on cognitive performance and, considering the protective causal role of BOHBUT, on AD. This concept might align with the beneficial effect of consuming a low-carbohydrate diet and perhaps coincide with the concept of adhering to set mealtime schedules, such as intermittent fasting, which was previously suggested to yield cognitive benefits [45]. It is important to emphasize that findings from our observational and genetic analyses do not inform about the potential immediate benefits of interventions aimed at elevating KB levels on cognitive performance. Further RCTs are needed to investigate these short-term effects. If similar outcomes are replicated in RCTs, short-term therapeutic interventions, like the adoption of a ketogenic diet or the use of ketone supplements, could be considered as a combined therapeutic strategy.

Our study provides a number of strengths that reinforce the validity of the findings. Firstly, KBs were measured using NMR spectroscopy, which is an advanced analytical technique allowing for the identification and precise quantification of metabolites. Secondly, the concordance of the effect direction in triangulating evidence from observational and MR studies strengthens the causal evidence observed between KBs and cognitive functions. In addition, one of the SNPs discovered in our in-house meta-analysis for KB is located near OXCT1, which is known to be in the pathway for KB catabolism [46]. Therefore, this partially reassures us that selected instrumental SNPs reflect an underlying mechanism of KB and as a consequence, a good proxy as an instrument variable.

Our study also has limitations that should be taken into consideration. Firstly, due to the challenge to control the fasting period before blood collection, there is a potential for measurement error. Higher levels of KB can be measured if individuals have longer fasting periods. This may affect the identification of the underlying KB SNPs that were used as instruments in MR analyses, as well as the results observed in our observational study. Secondly, our instrumental SNPs provide limited variance explained, i.e., 0.6% for BOHBUT and 0.5% for ACACE. Further discovery of underlying KB SNPs is required in the study with larger sample sizes. Thirdly, as mentioned above, we assumed a linear relationship between KB and cognitive performance. If this is not the case, the linear model would have a limited ability to capture nonlinear complexities in the data and may result in biased estimates. Lastly, our study is based on a sample consisting of Caucasian individuals; therefore, caution should be taken when generalizing the finding to other populations.

Conclusions

Using triangulating evidence from observational and MR studies, we observed an association and some evidence of a causal effect of BOHBUT on cognitive performance. Our study suggested that increased BOHBUT has a beneficial effect on cognitive performance. In addition, when considering the causal role of BOHBUT on AD, some protective causal effect was observed against this neurodegenerative disease. Our findings are consistent with a hypothesis that increased BOHBUT may improve cognitive function, contributing to decreased progression of cognitive impairment and risk of AD.

Acknowledgements

The authors acknowledge the invaluable discussions with Dr. Suntaree Unhapipat for the assistance in observational analyses.

A complete list of the UCLEB Consortium members can be found in Additional file 1.

Disclosures

TRG receives funding from GlaxoSmithKline and Biogen.

Declarations

For the UCLEB dataset, local research ethics committees provided ethical approval and participants gave written informed consent. Datasets of SSGAC and IGAP were public GWAS summary statistics, and ethics approval can be found in the original studies.

Not applicable.

Competing interests

TRG receives funding from GlaxoSmithKline and Biogen. The other authors declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Silva B, Mantha OL, Schor J, Pascual A, Placais PY, Pavlowsky A, et al. Glia fuel neurons with locally synthesized ketone bodies to sustain memory under starvation. Nat Metab. 2022;4(2):213–24.PubMedPubMedCentral

Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. 2020;21(22):8767.PubMedPubMedCentral

Achanta LB, Rowlands BD, Thomas DS, Housley GD, Rae CD. β-Hydroxybutyrate boosts mitochondrial and neuronal metabolism but is not preferred over glucose under activated conditions. Neurochem Res. 2017;42(6):1710–23.PubMed

Hu E, Du H, Zhu X, Wang L, Shang S, Wu X, et al. Beta-hydroxybutyrate promotes the expression of BDNF in hippocampal neurons under adequate glucose supply. Neuroscience. 2018;386:315–25.PubMed

Sleiman SF, Henry J, Al-Haddad R, El Hayek L, AbouHaidar E, Stringer T, et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body beta-hydroxybutyrate. Elife. 2016;5:e15092.PubMedPubMedCentral

Zhao M, Huang X, Cheng X, Lin X, Zhao T, Wu L, et al. Ketogenic diet improves the spatial memory impairment caused by exposure to hypobaric hypoxia through increased acetylation of histones in rats. PLoS ONE. 2017;12(3):e0174477.PubMedPubMedCentral

Versele R, Corsi M, Fuso A, Sevin E, Businaro R, Gosselet F, et al. Ketone bodies promote amyloid-beta1–40 clearance in a human in vitro blood-brain barrier model. Int J Mol Sci. 2020;21(3):934.PubMedPubMedCentral

Ota M, Matsuo J, Ishida I, Takano H, Yokoi Y, Hori H, et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer’s disease. Neurosci Lett. 2019;690:232–6.PubMed

Jensen NJ, Nilsson M, Ingerslev JS, Olsen DA, Fenger M, Svart M, et al. Effects of beta-hydroxybutyrate on cognition in patients with type 2 diabetes. Eur J Endocrinol. 2020;182(2):233–42.PubMed

10.

Ota M, Matsuo J, Ishida I, Hattori K, Teraishi T, Tonouchi H, et al. Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement. Psychopharmacology. 2016;233(21–22):3797–802.PubMed

11.

Fortier M, Castellano CA, St-Pierre V, Myette-Cote E, Langlois F, Roy M, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement. 2021;17(3):543–52.PubMed

12.

Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31.PubMed

13.

Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363.PubMedPubMedCentral

14.

Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5(6):311–22.PubMed

15.

Yin J, Nielsen M, Li S, Shi J. Ketones improves apolipoprotein E4-related memory deficiency via sirtuin 3. Aging (Albany NY). 2019;11(13):4579–86.PubMed

16.

Dhillon KK, Gupta S. Biochemistry, ketogenesis. StatPearls. Treasure Island (FL). 2022. https://www.ncbi.nlm.nih.gov/books/NBK493179/.

17.

Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25(1):42–52.PubMed

18.

Fritzsche I, Buhrdel P, Melcher R, Bohme HJ. Stability of ketone bodies in serum in dependence on storage time and storage temperature. Clin Lab. 2001;47(7–8):399–403.PubMed

19.

Shah T, Engmann J, Dale C, Shah S, White J, Giambartolomei C, et al. Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. PLoS ONE. 2013;8(8):e71345.PubMedPubMedCentral

20.

Elovainio M, Ferrie JE, Singh-Manoux A, Gimeno D, De Vogli R, Shipley MJ, et al. Cumulative exposure to high-strain and active jobs as predictors of cognitive function: the Whitehall II study. Occup Environ Med. 2009;66(1):32–7.PubMed

21.

Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50(8):1112–21.PubMedPubMedCentral

22.

Trampush JW, Yang ML, Yu J, Knowles E, Davies G, Liewald DC, et al. GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report from the COGENT Consortium. Mol Psychiatry. 2017;22(3):336–45.PubMedPubMedCentral

23.

Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun. 2018;9(1):2098.PubMedPubMedCentral

24.

Anderson JC, Mattar SG, Greenway FL, Lindquist RJ. Measuring ketone bodies for the monitoring of pathologic and therapeutic ketosis. Obes Sci Pract. 2021;7(5):646–56.PubMedPubMedCentral

25.

Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun. 2016;7:11122.PubMedPubMedCentral

26.

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.PubMedPubMedCentral

27.

Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8.PubMedPubMedCentral

28.

Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783–802.PubMedPubMedCentral

29.

Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14.PubMedPubMedCentral

30.

Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–98.PubMedPubMedCentral

31.

Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.PubMedPubMedCentral

32.

Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.PubMedPubMedCentral

33.

Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755–64.PubMed

34.

Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization with fine-mapped genetic data: choosing from large numbers of correlated instrumental variables. Genet Epidemiol. 2017;41(8):714–25.PubMedPubMedCentral

35.

Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734–9.PubMedPubMedCentral

36.

Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15(6):412–26.PubMed

37.

White H, Heffernan AJ, Worrall S, Grunsfeld A, Thomas M. A systematic review of intravenous beta-hydroxybutyrate use in humans - a promising future therapy? Front Med (Lausanne). 2021;8:740374.PubMed

38.

Kanikarla-Marie P, Jain SK. Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes. Free Radic Biol Med. 2016;95:268–77.PubMedPubMedCentral

39.

Lacy ME, Gilsanz P, Eng CW, Beeri MS, Karter AJ, Whitmer RA. Recurrent diabetic ketoacidosis and cognitive function among older adults with type 1 diabetes: findings from the Study of Longevity in Diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001173.PubMedPubMedCentral

40.

Baldo JV, Shimamura AP, Delis DC, Kramer J, Kaplan E. Verbal and design fluency in patients with frontal lobe lesions. J Int Neuropsychol Soc. 2001;7(5):586–96.PubMed

41.

Funahashi S. Working memory in the prefrontal cortex. Brain Sci. 2017;7(5):49.

42.

Baddeley A, Jarrold C, Vargha-Khadem F. Working memory and the hippocampus. J Cogn Neurosci. 2011;23(12):3855–61.PubMed

43.

Takeuchi H, Taki Y, Hashizume H, Sassa Y, Nagase T, Nouchi R, et al. Effects of training of processing speed on neural systems. J Neurosci. 2011;31(34):12139–48.PubMedPubMedCentral

44.

Chevalier N, Kurth S, Doucette MR, Wiseheart M, Deoni SC, Dean DC 3rd, et al. Myelination is associated with processing speed in early childhood: preliminary insights. PLoS ONE. 2015;10(10):e0139897.PubMedPubMedCentral

45.

Elias A, Padinjakara N, Lautenschlager NT. Effects of intermittent fasting on cognitive health and Alzheimer’s disease. Nutr Rev. 2023;81(9):1225–33.PubMedPubMedCentral

46.

Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(8):H1060–76.PubMedPubMedCentral

Titel: Triangulating evidence from observational and Mendelian randomization studies of ketone bodies for cognitive performance
verfasst von: Wichanon Sae-jie
Suangsuda Supasai
Mika Kivimaki
Jackie F. Price
Andrew Wong
Meena Kumari
Jorgen Engmann
Tina Shah
Amand F. Schmidt
Tom R. Gaunt
Aroon Hingorani
Pimphen Charoen
on behalf of the UCLEB Consortium
Publikationsdatum: 01.12.2023
Verlag: BioMed Central
Erschienen in: BMC Medicine / Ausgabe 1/2023
Elektronische ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-023-03047-7

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 49 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Diabetestechnologie für alle?

15.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Eine verbesserte Stoffwechseleinstellung und höhere Lebensqualität – Diabetestechnologien sollen den Alltag der Patienten erleichtern. Dass CGM, AID & Co. bei Typ-1-Diabetes helfen, ist belegt. Bei Typ-2 gestaltet sich die Sache komplizierter.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Supplementary Information

Publisher’s Note

Background

Methods

Observational study

Datasets for observational study

Observational analyses

Mendelian randomization study

Datasets for Mendelian randomization

Exposure data: ketone bodies

Outcome data: cognitive performance

Two-sample Mendelian randomization analyses

Results

Participant characteristics

Observational study

Mendelian randomization study

Selection of instrumental variants

Causal effects of KBs on cognitive performance

Causal effects of KBs on Alzheimer’s disease

Causal effect estimation with cis-MR

Discussion

Conclusions

Acknowledgements

Disclosures

Declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Supplementary Information

Weitere Artikel der Ausgabe 1/2023

Coding long COVID: characterizing a new disease through an ICD-10 lens

Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts

Socioeconomic representativeness of Australian, Canadian and British cohorts from the paediatric diabetes AdDIT study: comparisons to regional and national data

CSF1R regulates schizophrenia-related stress response and vascular association of microglia/macrophages

NICE and NHS England leads the way to improve diabetes care with access to continuous glucose monitoring for people with type 1 diabetes

Autophagy-related genes analysis reveals potential biomarkers for prediction of the impaired walking capacity of peripheral arterial disease

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Diabetestechnologie für alle?

Update Allgemeinmedizin